P ercutaneous coronary intervention (PCI) for ST-segmentelevation myocardial infarction and an early invasive strategy, which may include PCI, for non-ST-segmentelevation acute coronary syndrome (NSTEACS) are associated with improved clinical outcomes. 1,2 Such patients receive multiple adjunctive antithrombotic therapies, which increase bleeding risk. In acute coronary syndromes, bleeding is a significant predictor of morbidity and mortality. 3 Although access-site complications represent an important source of bleeding, especially when transfemoral access (TFA) is used, 4-6 in NSTEACS, access-site bleeding accounts for a smaller proportion of bleeding events compared with Background-Compared with transfemoral access, transradial access (TRA) for percutaneous coronary intervention is associated with reduced risk of bleeding and vascular complications. Studies suggest that TRA may reduce mortality in patients with ST-segment-elevation myocardial infarction. However, there are few data on the effect of TRA on mortality, specifically, in patients with non-ST-segment-elevation myocardial infarction.
nonaccess-site bleeding. 7 Transradial access (TRA) has been shown to reduce access site-related bleeding, vascular complications, and mortality after PCI. [8] [9] [10] Although a reduction in bleeding with TRA may translate to a mortality benefit, factors other than bleeding may play a role. 11 Recent randomized-controlled trials, Radial Versus Femoral Access for Coronary Intervention (RIVAL) and Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome (RIFLE-STEACS), have demonstrated that TRA reduces mortality in patients with ST-segment-elevation myocardial infarction. 7, 12 In RIVAL, TRA did not demonstrate mortality benefit in patients with NSTEACS. However, only 62% of these patients had positive cardiac biomarkers. 7 Whether TRA confers prognostic benefit in the high-risk NSTEACS group, that is, with positive cardiac biomarkers, remains to be determined. In this study, we sought to determine whether TRA is associated with better clinical outcomes in patients with non-ST-segment-elevation myocardial infarction (NSTEMI; NSTEACS with a positive troponin) treated with PCI.
Methods
This was a retrospective observational cohort study to investigate the relationship between arterial access site and outcome after PCI for NSTEMI. We used merged data sets from local British Cardiac Intervention Society (BCIS) databases, which contribute to the BCIS national database.
BCIS-National Institute for Cardiovascular Outcomes Research Database
The BCIS-National Institute for Cardiovascular Outcomes Research database collects data from all hospitals in United Kingdom that perform PCI, recording information about every procedure performed. 13 Data are collected prospectively at each hospital, electronically encrypted, and transferred online to a central database. Patients' survival data are obtained by linkage of patients' National Health Service numbers to the Office of National Statistics.
Population Study and Design
We examined an observational cohort of consecutive patients with NSTEMI treated with PCI between January 4, 2005, and November 18, 2011, at all 8 tertiary cardiac centers in London, United Kingdom. Patient and procedural details were recorded at the time of the procedure and during the admission into each center's local BCIS database. Anonymous data sets with linked mortality data were merged for analysis. Initially, 16 185 patients were identified as patients with NSTEACS who underwent PCI. A total of 19 patients were recorded as having transbrachial access and were removed from the cohort. A total of 119 patients had both TRA and TFA recorded indicating likely access crossover sites. Because initial access site could not be determined, these were removed from the analysis. Of the remaining 16 047 patients, defining NSTEMI by a positive troponin value, 10 095 patients were included in the final analysis ( Figure I 
Clinical Outcomes
Bleeding and access-site complications were recorded during the admission. All-cause mortality was obtained by linkage to the Office of National Statistics (England and Wales). Bleeding was defined as access-site bleeding, gastrointestinal bleeding, cardiac tamponade, intracranial hemorrhage, or blood transfusion. Access-site bleeding was defined as large hematomas (greater than what would be normally expected), 7 retroperitoneal bleeding, and pseudoaneurysm formation. Major bleeding was defined as bleeding (as above) but only included large hematomas requiring blood transfusion.
Ethics
All patient identifiable information was removed before database merging and analysis. Because this analysis was performed on anonymised data from mandatory audit, the local ethics committee advised us that ethical approval was not required.
Statistical Analyses
Patients were divided into femoral and radial groups. Noncategorical variables were summarized using median (lower and upper quartiles) and compared using the Mann--Whitney U test. Categorical variables were expressed as percentages and compared using the Z test. To determine predictors for mortality, Cox proportional hazards regression models were used to provide adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). To determine predictors of bleeding and access-site complications during the admission, logistic regression models were used to provide adjusted odds ratios (ORs) with associated 95% CIs. Landmark analyses were used to determine whether any difference in long-term outcomes was because of maintenance of short-term effects or additional effects beyond 30 days. To account for measured confounding, propensity matching was performed. To account for unmeasured confounding, an instrumental variable analysis was performed using center-specific radial access rate (low versus high) as the instrumental variable. Details of statistical methodology are provided in the methods in the Data Supplement. Statistical significance was established at P<0.05 (2-tailed) for all tests. All data are reported according to the STrengthening the Reporting of OBservational studies in Epidemiology guidelines.
Results

Baseline Population and Procedural Characteristics
We analyzed 10 095 consecutive patients with NSTEMI who underwent PCI across all 8 tertiary cardiac centers in London, United Kingdom. There were 7820 patients in the TFA group and 2275 patients in the TRA group. The baseline demographic, clinical, and procedural characteristics are summarized in Table 1 .
WHAT IS KNOWN
• In patients undergoing percutaneous coronary intervention, transradial access reduces access-site bleeding and complications.
• Although transradial access is associated with reduced mortality in patients undergoing primary percutaneous coronary intervention for ST-segmentelevation myocardial infarction, a mortality benefit in other patient populations has not been shown.
WHAT THE STUDY ADDS
• In this study examining the role of vascular access in patients with non-ST-segment-elevation myocardial infarction, transradial access was associated with reduced bleeding, access site complications, and allcause mortality.
• This study also demonstrates that the learning curve and experience in transradial percutaneous coronary intervention may be important factors contributing to the prognostic benefit conferred with transradial access.
Trends in Radial Access Use
During the 6-year period, TRA was used in 23% of patients. There was a significant increase in TRA use over this period (7% in 2005, 21% in 2008, and 40% in 2011). The case complexity and the proportion of high-risk patients treated with PCI also increased over time. Comparing the time periods (2005-2007 versus 2008-2011), there was an increase in the proportion of complex cases treated using TRA, with an increase in left main stem artery intervention (11.0% versus 8.7%), graft intervention (14.1% versus 6.6%), multivessel intervention (27.3% versus 15.2%), and chronic total occlusion intervention (25.6% versus 10.7%). Furthermore, there was increased use of TRA in high-risk patients (eg, those presenting with cardiogenic shock [19.4% versus 12.5%] and those requiring intra-aortic balloon pump [15.2% versus 2.7%]). These data demonstrate the learning curve and an increase in the experience and expertise in transradial PCI during the study period ( Figure 1 ).
Unadjusted Outcomes
The overall bleeding rate was lower in the TRA group (0.2% versus 1.0%; P<0.001), which was driven by access-site bleeding (0.2% versus 0.7%; P=0.003). When examining major bleeding events, this was also lower in the TRA group (0.1% versus 0.7%; P<0.001). TRA was associated with lower mortality rates at 30 days (1.2% versus 2.1%; P=0.007), at 6 months (2.5% versus 4.2%; P<0.001), and at 1 year (4.0% versus 5.9%; P=0.001).
Adjusted Multivariable Models
Access-Site and Bleeding Complications
Multivariable analysis identified TRA as predictor for reduced total bleeding (OR=0.21; 95% CI: 0.08-0.57; P=0.002) and major bleeding (OR=0.21; 95% CI: 0.07-0.69; P=0.009). Predictors for increased bleeding included peripheral vascular disease, female sex, and previous cerebrovascular accident. Furthermore, TRA access remained a predictor for reduced access-site complications (OR=0.47; 95% CI: 0.23-0.95; P=0.034) and reduced access-site bleeding (OR=0.28; 95% CI: 0.10-0.78; P=0.015). To determine whether there was a relationship with bleeding and mortality, we used multivariable models adjusting for all significant predictors of bleeding and mortality. This did not demonstrate a statistically significant association between an in-hospital bleeding event and mortality at 1 year (HR=1.48; 95% CI: 0.65-3.34; P=0.348), but a major in-hospital bleeding event was a predictor of increased mortality at 1 year (HR=2.56; 95% CI: 1.13-5.80; P=0.024).
Mortality
Multivariable analysis identified TRA as a predictor for mortality at 30 days (HR=0.53; 95% CI: 0.31-0.91; P=0.021), 6 months (HR=0.60; 95% CI: 0.42-0.85; P=0.003), and 1 year (HR=0.72; 95% CI: 0.54-0.94; P=0.017). Consistent predictors for increased mortality included age, cardiogenic shock, intra-aortic balloon pump use, diabetes mellitus, left main stem artery intervention, left anterior descending artery intervention, previous myocardial infarction, and presence of multivessel disease. Although we adjusted for presence of multivessel disease and the vessel(s) intervened on, it may be important to account for any residual untreated disease. Defining residual disease as any stenosis >50% in any epicardial coronary artery, and adjusting for this additional covariate in the multivariable model, TRA remained a predictor for mortality at 30 days (HR=0.54; 95% CI: 0.32-0.92; P=0.025), 6 months (HR=0.60; 95% CI: 0.43-0.85; P=0.004), and 1 year (HR=0.72; 95% CI: 0.55-0.94; P=0.019).
Given the learning curve and increase in expertise in transradial PCI over time, the effect of TRA on mortality was examined for 2 time periods, 2005 to 2007 and 2008 to 2011. Between 2005 and 2007, TRA was not a predictor for mortality at 30 days (HR=0.63; 95% CI: 0.28-1.42; P=0.272), 6 months (HR=0.62; 95% CI: 0.34-1.13; P=0.112), and 1 year (HR=0.81; 95% CI: 0.51-1.28; P=0.376). However, between 2008 and 2011, TRA was a predictor for mortality at 30 days (HR=0.44; 95% CI: 0.22-0.91; P=0.023), 6 months (HR=0.57; 95% CI: 0.37-0.87; P=0.010), and 1 year (HR=0.65; 95% CI: 0.46-0.92; P=0.015). This would suggest that the prognostic benefit conferred with TRA use seems to be related to the learning curve and increased experience and expertise seen with TRA over time. Similarly, when comparing low versus high volume radial centers, the mortality benefit of TRA was not seen at the low-volume centers (30 days, HR=0.65, 95% CI: 0.23-1.80, P=0.409; 6 months, HR=0.55, 95% CI: 0.25-1.19, P=0.131; and 1 year, HR=0.80, 95% CI: 0.47-1.38, P=0.428) but specifically seen in the high volume radial centers (30 days, HR=0.52, 95% CI: 0.27-0.97, P=0.041; 6 months, HR=0.61, 95% CI: 0.41-0.90, P=0.014; and 1 year, HR=0.70, 95% CI: 0.51-0.97, P=0.031).
Propensity-Matched Analyses
Propensity score matching producing a total of 3432 matched patients (1716 in the TFA group and 1716 in the TRA group). The c-statistic for the propensity model was 0.70 (95% CI: 0.68-0.71), and the Hosmer-Lemeshow test yielded a P=0.334. All variables were well balanced in the 2 propensity-matched cohorts ( Table 1) , and the absolute standardized differences in means were all <10% (Figure 2 ). In addition, when stratifying the patients by quintiles of propensity scores, all variables were well balanced within each quintile with no statistically significant differences ( Table I in the Data Supplement). The Q-Q and jitter plots demonstrated good overlap of the propensity score distributions ( Figure II in the Data Supplement). In the propensity-matched cohorts, TRA was associated with significant reduction in mortality at 30 days (1.9% versus 0.8%; P=0.008), at 6 months (3.9% versus 1.9%; P<0.001), and at 1 year (5.1% versus 3.2%; P=0.004). Applying Cox multivariable regression analysis, TRA was a predictor for mortality at 30 days (HR=0.43; 95% CI: 0.22-0.87; P=0.019), 6 months (HR=0.43; 95% CI: 0.27-0.67; P<0.001), and 1 year (HR=0.60; 95% CI: 0.42-0.85; P=0.005). Consistent with findings from unmatched cohort analyses, TRA remained a predictor for bleeding (OR=0.18; 95% CI: 0.05-0.66; P=0.008), access-site bleeding (OR=0.11; 95% CI: 0.01-0.92; P=0.042), and access-site complications (OR=0.09; 95% CI: 0.01-0.76; P=0.027).
Landmark Analyses
The Kaplan-Meier curves for 30-day and 1-year mortality for both unmatched and propensity-matched cohorts are shown in Figure 3 . The curves diverge over a short-term period and then become almost parallel. Applying the landmark method, in a multivariable model for mortality for the 9902 patients who survived the first 30 days, there was no difference in mortality between TRA and TFA (HR=0.81; 95% CI: 0.59-1.11; P=0.192).
Instrumental Variable Analysis
To account for unmeasured confounding, instrumental variable (IV) analysis was performed using center radial access Discrete variables are presented as percentages and compared using the Z test (2-tailed); continuous data presented as medians (25%, 75% interquartile range) and compared using the Mann-Whitney U test (2-tailed). CVA indicates cerebrovascular accident; DES, drug-eluting stent; IABP, intra-aortic balloon pump; LAD, left anterior descending artery; LCx, left circumflex artery; LMS, left main stem artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; and RCA, right coronary artery.
*Renal disease was defined as serum creatinine >200 mmol/L or renal replacement therapy. †Smoking was defined as smoking of ≥1 cigarettes/d and had smoked in the month preceding PCI. ‡Cardiogenic shock was defined as a systolic blood pressure <90 mm Hg, pulse rate >100 bpm, and the need for inotropic drugs, intra-aortic balloon pump, or cardiopulmonary support.
§A diseased epicardial coronary vessel was defined as having a >50% coronary stenosis by visual estimation.
rate (low versus high) as an IV. The use of TRA was 10.1% versus 34.2% (low versus high groups; P<0.001), and the strong association between TRA use and the IV was validated using logistic regression and linear regression models. When stratifying patients by the IV, there was no difference in 1-year mortality (5.6% versus 5.4%; low versus high groups; P=0.691). The F test statistic for center radial access rate was 56.61 (value <10 indicates a weak IV). Table 2 demonstrates the strength of center radial access rate as an IV. When comparing baseline variables, with the exception of 2 covariates, there were small differences in covariates between the groups, but these differences were smaller than those observed when stratifying patients according to access site (Table 1) . However, such differences in covariates between IV-stratified groups are often reported in IV analyses. 14, 15 We also calculated the covariate imbalance using the Mahalanobis distance, which corrects for observed covariance among measured covariates. Stratification by the IV resulted in an 87% reduction in Mahalanobis distance, indicating a significant improvement in covariate balance. Adopting the framework proposed by Brookhart and Schneeweiss, 16 when examining the difference in TRA use among various patient subsets stratified according to the IV, the strength of the IV was similar to that in the overall cohort across most observed variables, with the exception of 4 variables. The balance in the distribution of most observed variables provided reasonable evidence to infer that balance of unmeasured variables is likely to be improved by IV stratification. TRA was found to be associated with reduced 1-year mortality, with an unadjusted absolute mortality difference of −1.8% (95% CI: −2.9% to −0.8%; P<0.001) and adjusted absolute mortality difference of −1.4% (95% CI: −2.3% to −0.6%; P=0.016). However, the IV-adjusted absolute mortality difference was −5.8% (95% CI: −11.3% to −0.3%; P=0.039). 
Discussion
This study sought to establish the association of vascular access site with clinical outcomes specifically in patients with NSTEMI. The results of this study have 3 key findings. First, TRA is associated with reduced bleeding and access-site complications, corroborating findings of other studies. Second, TRA is associated with a reduction in mortality in patients with NSTEMI, an effect which extends ≤1 year after PCI. Third, experience and expertise may be particularly important with TRA because the prognostic benefit conferred by TRA seems to be related to the growing experience in transradial PCI. Many observational and randomized studies have shown that TRA is associated with reduced bleeding and vascular complications after PCI. 9 However, the mortality benefit with TRA has only been demonstrated in patients with ST-segment-elevation myocardial infarction. 10 The RIVAL study also examined patients with NSTEACS, but less than two thirds of patients had positive troponin values. Although the RIVAL study found no difference in mortality in the NSTEACS population, this finding may not be directly applicable to patients with NSTEMI. Troponin elevation is a marker of increased risk, and these patients are more likely to receive more potent antithrombotic therapies 17 and thus have a greater bleeding risk. Consistent with this, in our data set, the use of glycoprotein IIb-IIIa inhibitors and bivalirudin was greater in those with a positive troponin compared with those with a negative troponin (29.8% versus 21.8%; P<0.001). There are no studies examining the role of vascular access exclusively in patients with NSTEMI, and this is the first study to describe an association of reduced mortality with TRA in this patient population. Although the benefit of TRA has been consistently demonstrated in high-risk patients with ST-segment-elevation myocardial infarction, the findings of this study would suggest that this benefit may also extend to the high-risk NSTEACS population.
The overall bleeding rates reported in this study are 0.80%, which are comparable to the non-coronary artery bypass surgery-related major bleeding rates reported in the NSTEACS cohort of the RIVAL study (0.79%). 18 The link between bleeding and poor clinical outcomes is complex and has a mutlifactorial basis. 19 Consistent with previous studies, we found TRA to be a predictor for reduced bleeding and access-site complications. Our data demonstrate that the occurrence of a major bleeding event was associated in increased 1-year mortality, corroborating previously reported findings. 3 A reduction in bleeding is considered to be the primary basis for mortality reduction with TRA. The results from the landmark analyses indicate that the mortality benefit conferred by TRA at 1 year was likely a result of differences in the periprocedural and early outcomes that was maintained in the long term. It would be unusual for TRA to be associated with increased mortality beyond 30 days because the survival benefit from TRA is likely to be through a reduction in bleeding, and the results of the landmark analysis seem to be consistent with this concept. Although some access site complications may not result in significant bleeding, they may still require intervention with consequent activation of systemic inflammation and coagulation all of which may increase cardiovascular risk.
To account for measured confounders, propensity-matched analyses demonstrated that TRA was associated with reduced mortality ≤1 year, confirming findings from unmatched cohorts. However, propensity-matched analyses do not account for unmeasured confounders, and so we applied IV analyses using center-specific radial access rate as an IV and analyzed mortality at 1 year, and this demonstrated that TRA was associated with an absolute mortality reduction of 5.8%. However, there were some differences in baseline covariates in the IV-stratified cohorts, but the differences were much smaller compared with access-site stratified cohorts. Although one can only infer that the balance of unmeasured confounders is improved, it is likely there may be still be residual unmeasured differences.
Numerous studies have demonstrated the steep learning curve associated with TRA. [20] [21] [22] In this study, there was a significant increase in the use of TRA over time. The growing experience and proficiency in TRA use were reflected by the increase in complexity of transradial procedures and the use of TRA in higher risk patients when comparing the 2005 to 2007 time period with the more contemporary 2008 to 2011 time period. This study also indicates that the experience and proficiency with TRA may contribute to the prognostic benefit seen with TRA because the mortality benefit with TRA was specifically seen over the 2008 to 2011 time period. To our knowledge, this is the first study to report how the prognostic benefit with TRA evolves with experience over time. The link between better outcomes and PCI procedural volume has been reported in many studies. 23, 24 In this study, the mortality benefit with TRA was specifically seen in the high volume radial centers, which corroborate findings reported in the RIVAL study. 14, 25 However, given that the HRs between low and high-volume centers are similar, particularly at 6 months, it is possible that the reduced patient numbers when stratified to center volumes may have a resulted in reduced power to detect a difference in the low-volume centers.
Strengths and Limitations of This Study
The strength of this study is that it includes patients with cardiogenic shock, peripheral vascular disease, and previous bypass surgery and thus representative of patients encountered in day-to-day clinical practice. Although inclusion of such patients may result in selection bias, this was addressed by statistical methods that account for measured and unmeasured confounders. This study has all the limitations of a registry and all the potential bias associated with nonrandomization. One cannot exclude the possibility of under-reporting of complications. We were not able to adjust for those missing variables and those not collected by the database (eg, sheath sizes were not recorded and may have been larger in patients with TFA); individual operator experience was not known, which may affect outcomes, especially with TRA; and although all patients received dual antiplatelet therapy, the timing of antiplatelet therapy was not recorded, which may have affected bleeding complications. On this basis, residual confounding cannot be excluded. A common limitation with observational studies examining vascular access is the lack of data on planned initial access and crossover rate. We were able to identify 119 patients as having had both TRA and TFA, indicating likely access-site crossover. Given the initial planned access could not be deduced, these were excluded from the analysis, excluding the possibility for confounding. Therefore, an intention-to-treat analysis was not possible. Bleeding complications were not categorized using classic bleeding scores. The definitions of a large hematoma and thresholds for blood transfusion are likely to have been variable between the different centers. To address potential variability in definitions of a large hematoma between the centers, we included a major bleeding category, which only included large hematomas requiring blood transfusion. This is likely to be more clinically meaningful because it only includes significant hematomas. The use of bivalirudin was low (<1%), and it is conceivable that a greater use of bivalirudin may have reduced bleeding complications. 26 
Conclusions
This observational study suggests a clinical benefit of TRA over TFA in patients with NSTEMI. In addition to being associated with reduced bleeding and access-site complications, TRA is also associated with a mortality benefit. These data also demonstrate that the evolving learning curve, experience, and expertise may be important factors contributing to the prognostic benefit conferred with TRA. This study lends support to the evaluation of TRA in NSTEMI with prospective, adequately-powered, randomized-controlled trials. Distribution of covariates between the groups and use of TRA within each subgroup when stratified instrumental variable (expressed as %). CI indicates confidence interval; CVA, cerebrovascular accident; DES, drug-eluting stent; IABP, intra-aortic balloon pump; LAD, left anterior descending artery; LCx, left circumflex artery; LMS, left main stem artery; MI, myocardial infarction; RCA, right coronary artery; and TRA, transradial access. *Variation in TRA use induced by the instrument for each covariate was larger or smaller than that observed in the overall cohort.
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